172 related articles for article (PubMed ID: 35170037)
1. Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies.
Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Shehata N; Charames GS; de Vrijer B; Clarke G; Pechlivanoglou P; Okun N; Kandel R; Dooley J; Higgins C; Ng V; Sikich N
Transfusion; 2022 May; 62(5):1089-1102. PubMed ID: 35170037
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive Fetal RhD Blood Group Genotyping: A Systematic Review of Economic Evaluations.
Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Higgins C; Shehata N; Okun N; de Vrijer B; Pechlivanoglou P; Ng V; Sikich N
J Obstet Gynaecol Can; 2021 Dec; 43(12):1416-1425.e5. PubMed ID: 34390866
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women.
Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I;
BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830
[TBL] [Abstract][Full Text] [Related]
5. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed.
van der Schoot CE; Tax GH; Rijnders RJ; de Haas M; Christiaens GC
Transfus Med Rev; 2003 Jan; 17(1):31-44. PubMed ID: 12522770
[TBL] [Abstract][Full Text] [Related]
6. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
Hawk AF; Chang EY; Shields SM; Simpson KN
Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
[TBL] [Abstract][Full Text] [Related]
7. Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping.
Stensrud M; Bævre MS; Alm IM; Wong HY; Herud I; Jacobsen B; de Vos DDJA; Stjern HE; Sørvoll IH; Barane JB; Bagås TE; Rasmussen M; Ulvahaug N; Wamstad V; Tomter G; Akkök CA
Fetal Diagn Ther; 2023; 50(4):276-281. PubMed ID: 37379821
[TBL] [Abstract][Full Text] [Related]
8. Costs and benefits of non-invasive fetal RhD determination.
Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
[TBL] [Abstract][Full Text] [Related]
9. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales.
Szczepura A; Osipenko L; Freeman K
BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood--a meta-analysis.
Geifman-Holtzman O; Grotegut CA; Gaughan JP
Am J Obstet Gynecol; 2006 Oct; 195(4):1163-73. PubMed ID: 17000250
[TBL] [Abstract][Full Text] [Related]
11. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
[TBL] [Abstract][Full Text] [Related]
12. Cell free fetal DNA to triage antenatal rhesus immune globulin: Is it really cost-effective in the United States?
Moise KJ; Hashmi SS; Markham K; Argoti PS; Bebbington M
Prenat Diagn; 2019 Feb; 39(3):238-247. PubMed ID: 30610742
[TBL] [Abstract][Full Text] [Related]
13. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop.
Clausen FB; Barrett AN;
Vox Sang; 2019 May; 114(4):386-393. PubMed ID: 30834546
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive fetal RHD and RHCE genotyping from maternal plasma in alloimmunized pregnancies.
Hromadnikova I; Vesela K; Benesova B; Nekovarova K; Duskova D; Vlk R; Spalova I; Gerychova R; Hakenova A; Rosenbaumova Z; Vlasin P; Vlachova A; Palasek V; Roznakova E; Calda P
Prenat Diagn; 2005 Dec; 25(12):1079-83. PubMed ID: 16231295
[TBL] [Abstract][Full Text] [Related]
17. Is the management of Rh-Rh incompatibility with noninvasive fetal Rh genotyping for targeted prophylaxis cost-effective in the Turkish population?
Demirel E; Kelekçi S; Ekmekci E; Şengül M; İri R; Atasever M
Turk J Med Sci; 2018 Feb; 48(1):1-4. PubMed ID: 29479934
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: A cost-effectiveness analysis.
Gordon LG; Hyland CA; Hyett JA; O'Brien H; Millard G; Flower RL; Gardener GJ
Prenat Diagn; 2017 Dec; 37(12):1245-1253. PubMed ID: 29096422
[TBL] [Abstract][Full Text] [Related]
19. No. 343-Routine Non-invasive Prenatal Prediction of Fetal RHD Genotype in Canada: The Time is Here.
Johnson JA; MacDonald K; Clarke G; Skoll A
J Obstet Gynaecol Can; 2017 May; 39(5):366-373. PubMed ID: 28454757
[TBL] [Abstract][Full Text] [Related]
20. The clinical utility of fetal cell sorting to determine prenatally fetal E/e or e/e Rh genotype from peripheral maternal blood.
Geifman-Holtzman O; Makhlouf F; Kaufman L; Gonchoroff NJ; Holtzman EJ
Am J Obstet Gynecol; 2000 Aug; 183(2):462-8. PubMed ID: 10942488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
